8-K: Geron Secures $375 Million in Funding, Reports Strong Initial RYTELO Sales

Geron Corporation has secured up to $375 million in funding through a royalty agreement and a debt facility, while also reporting $28.2 million in net product revenue for RYTELO in its first full quarter of sales.

Summary

• Geron Corporation has entered into a loan agreement with Pharmakon Advisors for a 5-year senior secured term loan facility of up to $250 million, divided into three tranches.
• The first tranche of $125 million was funded on November 1, 2024, and a portion was used to repay $86.5 million of existing debt.
• The remaining proceeds from the first tranche will be used for general corporate and working capital needs.
• The second tranche of $75 million and the third tranche of $50 million are available subject to certain conditions and a revenue milestone, respectively, and can be requested before December 31, 2025.
• The term loans mature on November 1, 2029, and bear interest at a variable rate of 5.75% plus three-month SOFR, with a SOFR floor of 3.00%.
• Geron also entered into a revenue participation agreement with Royalty Pharma, receiving $125 million upfront in exchange for tiered royalty payments on U.S. net sales of RYTELO.
• The royalty rates range from 7.75% on sales up to $500 million, 3.0% on sales between $500 million and $1 billion, and 1.0% on sales above $1 billion.
• Royalty payments are capped at 1.65 or 2.0 times the initial investment depending on the date the cap is reached.
• Geron reported $28.2 million in net product revenue for RYTELO in the third quarter of 2024, its first full quarter of sales.
• The company's net loss for the third quarter of 2024 was $26.4 million, or $0.04 per share.
• As of September 30, 2024, Geron had approximately $378.9 million in cash, cash equivalents, restricted cash, and marketable securities, which increases to $542.4 million on a pro forma basis after the new funding.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful launch of RYTELO, the significant funding secured, and the clear plans for future growth. The financial results are mixed, but the overall outlook is optimistic.

Positives

• The $375 million in funding significantly strengthens Geron's balance sheet and provides financial flexibility.
• The initial sales of RYTELO exceeded expectations, demonstrating strong commercial execution.
• The loan agreement has no financial covenants, providing operational flexibility.
• The company has a clear plan for potential EU launch of RYTELO in 2026.
• The company has sufficient financial resources to fund operations for at least the next 12 months.

Negatives

• The company reported a net loss of $26.4 million for the third quarter of 2024.
• The loan agreement is secured by substantially all of Geron's assets, including intellectual property.
• The company is subject to restrictive covenants under the loan agreement, limiting certain actions.
• The company is subject to a number of events of default under the loan agreement.
• The company is subject to prepayment premiums and makewhole amounts if the loan is prepaid before maturity.

Risks

• The company's success depends on the commercialization of RYTELO and its acceptance in the market.
• There are risks associated with regulatory approvals, including potential delays or rejections.
• The company faces risks related to manufacturing and supply of RYTELO.
• The company's financial projections are based on assumptions that may not materialize.
• The company is subject to risks related to the ongoing Phase 3 IMpactMF trial, including enrollment and death rates.
• The company is subject to risks related to the debt and royalty financing agreements, including compliance and satisfaction of obligations.

Future Outlook

Geron believes its existing cash, cash equivalents, and marketable securities, along with anticipated revenues from RYTELO sales, will be sufficient to fund its projected operating requirements for at least the next 12 months. The company plans to support the commercial launch of RYTELO in the U.S. and potentially in the EU, complete the Phase 3 IMpactMF trial, and invest in supply chain redundancy.

Management Comments

• John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, stated that the initial full quarter of product revenue from the U.S. launch exceeded expectations and demonstrates strong execution as a commercial company.
• Michelle Robertson, Geron's Executive Vice President, Chief Financial Officer, believes that the favorable terms in the financing transactions reflect the significant commercial potential of RYTELO and provide critical flexibility to fuel continued growth.
• Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma, stated that RYTELO is an important therapy for the lower-risk MDS patient population and they look forward to its development in other hematologic malignancy indications.
• Pedro Gonzalez de Cosio, Chief Executive Officer of Pharmakon Advisors, LP, stated that the Geron team is driving commercial success in the U.S. with RYTELO and they look forward to supporting the company as they plan for a potential launch in the EU.

Industry Context

This announcement comes as Geron is transitioning into a commercial-stage company following the FDA approval of RYTELO. The funding and initial sales figures are critical for the company's growth and expansion in the competitive biopharmaceutical market, particularly in the area of hematologic malignancies. The partnership with Royalty Pharma and Pharmakon Advisors highlights the growing interest in innovative therapies for blood cancers.

Comparison to Industry Standards

• Geron's $28.2 million in first full quarter sales of RYTELO is a strong start for a newly launched oncology product, but it is difficult to compare directly to other companies without knowing the specific market size and penetration rates for similar drugs.
• The tiered royalty structure with Royalty Pharma is a common financing method in the biotech industry, allowing companies to access capital while sharing future revenue potential.
• The 5-year senior secured term loan with Pharmakon is a typical debt financing structure for a company at Geron's stage, providing non-dilutive capital.
• Companies like Karyopharm Therapeutics and Agios Pharmaceuticals, which also focus on hematologic malignancies, have used similar financing strategies to support their commercial launches and clinical development programs.
• The lack of financial covenants in the loan agreement is favorable for Geron, providing more operational flexibility compared to some other biotech companies that have more restrictive debt agreements.

Management Changes

Stakeholder Impact

• Shareholders will benefit from the increased financial stability and growth potential of the company.
• Employees will have more job security and opportunities for advancement.
• Patients will have access to a new treatment option for lower-risk MDS.
• Customers (healthcare providers) will have a new product to offer their patients.
• Suppliers will have increased business opportunities with Geron.
• Creditors will have a higher likelihood of repayment due to the improved financial position of the company.

Next Steps

• Geron will continue to commercialize RYTELO in the U.S.
• The company will prepare for a potential launch of RYTELO in the EU, subject to regulatory approval.
• Geron will continue to enroll patients in the Phase 3 IMpactMF trial.
• The company will present new data at the upcoming American Society for Hematology (ASH) Annual Meeting.
• Geron will monitor the review of the Marketing Authorization Application (MAA) for RYTELO in the EU.

Key Dates

Keywords

RYTELO, imetelstat, myelodysplastic syndromes, MDS, Royalty Pharma, Pharmakon Advisors, loan agreement, revenue participation, financing, commercial launch, hematologic malignancies, telomerase inhibitor